These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 23712327

  • 1. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
    Shi M, Lou B, Ji J, Shi H, Zhou C, Yu Y, Liu B, Zhu Z, Zhang J.
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
    [Abstract] [Full Text] [Related]

  • 2. Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin‑induced Src activation in gastric cancer cells.
    Zhou C, Ji J, Shi M, Yang L, Yu Y, Liu B, Zhu Z, Zhang J.
    Mol Med Rep; 2014 Nov; 10(5):2729-35. PubMed ID: 25199623
    [Abstract] [Full Text] [Related]

  • 3. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
    Luo FR, Barrett YC, Yang Z, Camuso A, McGlinchey K, Wen ML, Smykla R, Fager K, Wild R, Palme H, Galbraith S, Blackwood-Chirchir A, Lee FY.
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
    Wang L, Guo B, Wang R, Jiang Y, Qin S, Liang S, Zhao Y, Guo W, Li K, Fan X.
    Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
    [Abstract] [Full Text] [Related]

  • 5. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
    Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE.
    Cancer Res; 2009 May 01; 69(9):3842-9. PubMed ID: 19383922
    [Abstract] [Full Text] [Related]

  • 6. Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing.
    Herold CI, Chadaram V, Peterson BL, Marcom PK, Hopkins J, Kimmick GG, Favaro J, Hamilton E, Welch RA, Bacus S, Blackwell KL.
    Clin Cancer Res; 2011 Sep 15; 17(18):6061-70. PubMed ID: 21810917
    [Abstract] [Full Text] [Related]

  • 7. Targeting SRC in mucinous ovarian carcinoma.
    Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MM, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AK.
    Clin Cancer Res; 2011 Aug 15; 17(16):5367-78. PubMed ID: 21737505
    [Abstract] [Full Text] [Related]

  • 8. SRC signaling is crucial in the growth of synovial sarcoma cells.
    Michels S, Trautmann M, Sievers E, Kindler D, Huss S, Renner M, Friedrichs N, Kirfel J, Steiner S, Endl E, Wurst P, Heukamp L, Penzel R, Larsson O, Kawai A, Tanaka S, Sonobe H, Schirmacher P, Mechtersheimer G, Wardelmann E, Büttner R, Hartmann W.
    Cancer Res; 2013 Apr 15; 73(8):2518-28. PubMed ID: 23580575
    [Abstract] [Full Text] [Related]

  • 9. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
    Gomes EG, Connelly SF, Summy JM.
    Pancreas; 2013 Jul 15; 42(5):795-806. PubMed ID: 23271399
    [Abstract] [Full Text] [Related]

  • 10. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
    Johnson FM, Saigal B, Tran H, Donato NJ.
    Clin Cancer Res; 2007 Jul 15; 13(14):4233-44. PubMed ID: 17634553
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
    Nukatsuka M, Nakagawa F, Takechi T.
    Anticancer Res; 2015 Sep 15; 35(9):4605-15. PubMed ID: 26254349
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of Src impairs the growth of met-addicted gastric tumors.
    Bertotti A, Bracco C, Girolami F, Torti D, Gastaldi S, Galimi F, Medico E, Elvin P, Comoglio PM, Trusolino L.
    Clin Cancer Res; 2010 Aug 01; 16(15):3933-43. PubMed ID: 20628031
    [Abstract] [Full Text] [Related]

  • 13. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL.
    Oncogene; 2011 Feb 03; 30(5):561-74. PubMed ID: 20956938
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
    Hingorani P, Zhang W, Gorlick R, Kolb EA.
    Clin Cancer Res; 2009 May 15; 15(10):3416-22. PubMed ID: 19447875
    [Abstract] [Full Text] [Related]

  • 15. Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.
    Okamoto W, Okamoto I, Yoshida T, Okamoto K, Takezawa K, Hatashita E, Yamada Y, Kuwata K, Arao T, Yanagihara K, Fukuoka M, Nishio K, Nakagawa K.
    Mol Cancer Ther; 2010 May 15; 9(5):1188-97. PubMed ID: 20406949
    [Abstract] [Full Text] [Related]

  • 16. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
    Seoane S, Montero JC, Ocaña A, Pandiella A.
    J Natl Cancer Inst; 2010 Sep 22; 102(18):1432-46. PubMed ID: 20811002
    [Abstract] [Full Text] [Related]

  • 17. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
    Eustace AJ, Crown J, Clynes M, O'Donovan N.
    J Transl Med; 2008 Sep 29; 6():53. PubMed ID: 18823558
    [Abstract] [Full Text] [Related]

  • 18. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
    Kim EM, Mueller K, Gartner E, Boerner J.
    J Surg Res; 2013 Nov 29; 185(1):231-9. PubMed ID: 23899511
    [Abstract] [Full Text] [Related]

  • 19. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
    Cejka D, Preusser M, Fuereder T, Sieghart W, Werzowa J, Strommer S, Wacheck V.
    Anticancer Res; 2008 Nov 29; 28(6A):3801-8. PubMed ID: 19189667
    [Abstract] [Full Text] [Related]

  • 20. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
    Lee KW, Kim SG, Kim HP, Kwon E, You J, Choi HJ, Park JH, Kang BC, Im SA, Kim TY, Kim WH, Bang YJ.
    Cancer Res; 2008 Mar 15; 68(6):1916-26. PubMed ID: 18339873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.